XML 48 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Lease
12 Months Ended
Dec. 31, 2023
Lease [Abstract]  
LEASE

14. LEASE

 

As of December 31, 2023, the Group has two long-term operating leases for laboratories and clinic with remaining terms expiring from 2024 through 2026 and a weighted average remaining lease term of 1.9 years. Weighted average discount rates used in the calculation of the operating lease liability is 8%.

 

   For the year
ended
December 31,
2023
   For the year
ended
December 31,
2022
 
Lease cost        
Finance lease cost:        
Depreciation  $-   $47,818 
Interest on lease liabilities   -    1,435 
Operating lease cost   252,345    349,031 
Short-term lease cost   65,221    85,598 
Variable lease cost   
-
    
-
 
Sublease income   
-
    
-
 
Total lease cost  $317,566   $483,882 
           
Other information          
Cash paid for amounts included in the measurement of lease liabilities          
Operating cash flows from operating leases  $389,365   $369,505 
Financing cash flows from finance leases   -    49,358 
Right-of-use assets obtained in exchange for new operating lease liabilities   338,525    549,596 
Weighted-average remaining lease term – finance leases   
-
    - 
Weighted-average remaining lease term – operating leases   1.9 years    1.1 years 
Weighted-average discount rate – finance leases   -%   2.5%
Weighted-average discount rate – operating leases   8.0%   8.0%

 

For the year ended December 31, 2023, an impairment loss of $200,916 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of a right-of-use asset related to a lease of clinic may not be recoverable. Additionally, the Group early terminated a lease agreement for a right-of-use asset relating to an office, which resulted in a recognized loss on early termination of the right-of-use asset totaling $31,030 in other operating expenses. For the years ended December 31, 2022 and 2021, the Group did not recognize any impairment losses and loss on disposal of right-of-use assets.

 

The maturity analysis of operating leases liabilities as of December 31, 2023 is as follows:

 

   December 31,
2023
 
Remaining periods ending December 31,    
2024  $120,824 
2025   97,541 
2026   24,573 
Total future undiscounted cash flow   242,938 
Less: Discount on operating lease liabilities   (18,221)
Present value of operating lease liabilities   224,717 
Less: Current portion of operating lease liabilities   (125,232)
Non-current portion of operating lease liabilities  $99,485